skyebiologics.comSkye Biologics

Technology Products Clinical Pipeline Sign In Contact Back Current Commercialized Products Wound Care Ocular Back About Licenses & Certificates Events News Back Customer Portal Physician Portal Technology Products Current Commercialized Products Wound Care Ocular Clinical Pipeline About Licenses & Certificates Events News Sign In Customer Portal Physician Portal Contact Scroll Advancing the Frontier of Biologic Therapies is relentlessly committed to maximizing therapeutic potential by harnessing the power of human biology to treat patients suffering from degenerative disease, damaged tissue, injury, and trauma. As one ages, the body’s ability to repair and remodel decreases, causing what is called a broken healing-loop due to a lack of native functional tissue. Employing innovative science, Skye is discovering and developing breakthrough therapeutics that hack and optimize the repair process that leads to organized advanced healing with minimal scarring, complications, failure, or re-injury. Our novel approach begins with a platform of naturally advanced human biological material from which we have unraveled the code of complex molecules, isolating and applying them to treat a multitude of conditions across a range of surgical and non-surgical specialties – orthopedics, spine, sports medicine, chronic and complex wounds, plastic surgery, urology, gynecology and general surgery. Targeted therapies under development have the power to help upwards of 50 million patients per year. Active Clinical Pipeline → Maximum Preservation. BioECM® preservation utilizes the richest natural intact allograft tissue known to exist. With our novel HydraTek® technology, we can maximize preservation and potential through our unique preservation system, to further advance medical treatments. Skye® products provide distinct tissue and safety advantages over traditional human allograft or xenograft tissue sources. Placental tissues provide the most abundant source of an extracellular matrix (ECM). Learn More→ Technology Extracellular matrix preservation (BioECM) technology. LEARN MORE→ Pipeline Medicines with breakaway potential. LEARN MORE→ Products Industry leading unique tissue transplants. LEARN MORE→ Who we are. Addressing a $100 billion market, Skye is rapidly advancing multiple future regenerative biological therapies that will target all areas of the musculoskeletal system, internal tissue structures and areas where there is a high-unmet medical need and leverages its platform and expertise. We are dedicated and strive to accelerate to market regenerative solutions that improve health outcomes and dramatically improve people’s lives. A biotech leader since 2010, Skye has grown to be one of the world’s leading independent new age biotechnology companies , has reached hundreds of thousands of patients in the US with existing tissue products and is developing a pipeline of medicines with breakaway potential for decades to come. Contact Us→ Home Header Industry Home Gallery Who we are Technology Products Clinical Pipeline Contact ©2024 Holdings,...